Soligenix Inc

NASDAQ:SNGX   3:58:05 PM EDT
1.03
0.00 (0.00%)
4:35:58 PM EDT: $1.03 0.00 (0.00%)
Products

FDA Grants Soligenix Orphan Drug Designation For Treatment Of T-Cell Lymphoma

Published: 09/09/2021 11:39 GMT
Soligenix Inc (SNGX) - FDA Grants Soligenix Orphan Drug Designation for the Treatment of T-cell Lymphoma.